Titre : Cellules HepG2

Cellules HepG2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Chromatin Assembly and Disassembly
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules HepG2 : Questions médicales les plus fréquentes", "headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-11", "dateModified": "2025-02-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules HepG2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hépatocytes", "url": "https://questionsmedicales.fr/mesh/D022781", "about": { "@type": "MedicalCondition", "name": "Hépatocytes", "code": { "@type": "MedicalCode", "code": "D022781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436.348" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules HepG2", "alternateName": "Hep G2 Cells", "code": { "@type": "MedicalCode", "code": "D056945", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wilson de Melo Cruvinel", "url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com." } }, { "@type": "Person", "name": "Paulo Luiz Carvalho Francescantonio", "url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil." } }, { "@type": "Person", "name": "Alessandra Dellavance", "url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance", "affiliation": { "@type": "Organization", "name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil." } }, { "@type": "Person", "name": "Luis Eduardo Coelho Andrade", "url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade", "affiliation": { "@type": "Organization", "name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br." } }, { "@type": "Person", "name": "Antônio Carlos Ximenes", "url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes", "affiliation": { "@type": "Organization", "name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Saccharomyces cerevisiae Yta7 ATPase hexamer contains a unique bromodomain tier that functions in nucleosome disassembly.", "datePublished": "2022-12-30", "url": "https://questionsmedicales.fr/article/36592926", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbc.2022.102852" } }, { "@type": "ScholarlyArticle", "name": "The Dynamics of Viruslike Capsid Assembly and Disassembly.", "datePublished": "2022-07-06", "url": "https://questionsmedicales.fr/article/35792573", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/jacs.2c04074" } }, { "@type": "ScholarlyArticle", "name": "Obstacles and opportunities for base excision repair in chromatin.", "datePublished": "2022-05-28", "url": "https://questionsmedicales.fr/article/35689883", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.dnarep.2022.103345" } }, { "@type": "ScholarlyArticle", "name": "Pyruvate metabolism controls chromatin remodeling during CD4", "datePublished": "2023-06-01", "url": "https://questionsmedicales.fr/article/37267106", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.celrep.2023.112583" } }, { "@type": "ScholarlyArticle", "name": "ATP-Dependent Chromatin Remodellers in Inner Ear Development.", "datePublished": "2023-02-07", "url": "https://questionsmedicales.fr/article/36831199", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cells12040532" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Hépatocytes", "item": "https://questionsmedicales.fr/mesh/D022781" }, { "@type": "ListItem", "position": 5, "name": "Cellules HepG2", "item": "https://questionsmedicales.fr/mesh/D056945" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules HepG2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules HepG2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules HepG2", "description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules HepG2", "description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules HepG2", "description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules HepG2", "description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules HepG2", "description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules HepG2", "description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Chromatin+Assembly+and+Disassembly&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules HepG2 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les HepG2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules HepG2 présentent-elles des symptômes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux cellules HepG2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques." } }, { "@type": "Question", "name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques." } }, { "@type": "Question", "name": "Comment les HepG2 contribuent-elles à la recherche préventive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique." } }, { "@type": "Question", "name": "Peut-on utiliser HepG2 pour tester des médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments." } }, { "@type": "Question", "name": "Comment les HepG2 aident-elles à développer des traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec HepG2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées." } }, { "@type": "Question", "name": "Les HepG2 aident-elles à comprendre les complications du foie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec HepG2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés." } }, { "@type": "Question", "name": "Comment HepG2 aide à identifier des facteurs de risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques." } } ] } ] }

Sources (10000 au total)

The Saccharomyces cerevisiae Yta7 ATPase hexamer contains a unique bromodomain tier that functions in nucleosome disassembly.

The Saccharomyces cerevisiae Yta7 is a chromatin remodeler harboring a histone-interacting bromodomain (BRD) and two AAA+ modules. It is not well understood how Yta7 recognizes the histone H3 tail to ...

Landscape of chromatin remodeling gene alterations in endometrial carcinoma.

Chromatin remodeling genes (CRGs) encode components of epigenetic regulatory mechanisms and alterations in these genes have been identified in several tumor types, including gynecologic cancers. In th... We performed a retrospective analysis of 660 ECs sequenced using a clinical massively parallel sequencing assay targeting up to 468 genes, including 25 CRGs, and defined the presence of somatic CRG al... Of the 660 ECs sequenced, 438 (66.4%) harbored CRG alterations covered by our panel. The most commonly altered CRG was ARID1A (46%), followed by CTCF (21%), KMT2D (18%), KMT2B (17%), BCOR (16%), ARID1... CRG alterations are common in EC and are associated with clinicopathologic features and likely play a crucial role in EC....